Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALPL | P05186 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.44 |
| ▸ | CRHR1 | P34998 | 4/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31612706 | 0.78 | CRHR1 (0.41) | LMNATSHRSMN1; SMN2CRHR1LIPG | |
| SCHEMBL27749280 | 0.78 | LMNA (0.41) | LMNATSHRSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL7979529 | 0.78 | GAA (0.46) | LMNATSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL7521251 | 0.76 | LMNA (0.58) | LMNATSHRSMN1; SMN2HPGDKDM4E | |
| SCHEMBL24583509 | 0.76 | NPC1 (0.37) | LMNATSHRSMN1; SMN2HPGDP2RX7 | |
| SCHEMBL29696803 | 0.76 | CRHR1 (0.41) | LMNATSHRSMN1; SMN2CRHR1 | |
| SCHEMBL25216336 | 0.76 | CRHR1 (0.41) | LMNATSHRSMN1; SMN2CRHR1 | |
| SCHEMBL29696783 | 0.76 | NPC1 (0.37) | LMNATSHRSMN1; SMN2HPGDP2RX7 | |
| SCHEMBL24583789 | 0.76 | TTK (0.39) | LMNATSHRSMN1; SMN2HPGDP2RX7 | |
| SCHEMBL24582705 | 0.74 | LMNA (0.51) | LMNATSHRSMN1; SMN2CRHR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| WO-2010001946-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | アステラス製薬株式会社 (JP) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | HSD11B1, HSD11B2, HSD3B1 | LMNA 4210/4885TSHR 690/4885SMN1; SMN2 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.